{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001860657","name":"Allarity Therapeutics, Inc.","summary":"Allarity Therapeutics is a clinical-stage precision medicine pharmaceutical company focused on developing anti-cancer therapeutics using its proprietary Drug Response Predictor (DRP) platform. The DRP platform identifies gene expression signatures predicting cancer cell sensitivity to specific therapeutics, enabling patient selection for trials. The company is singularly focused on stenoparib, a dual PARP/tankyrase inhibitor in-licensed from Eisai Pharmaceuticals, being studied in platinum-resistant ovarian cancer and small cell lung cancer, alongside the stenoparib-DRP companion diagnostic.","people":[],"products":[{"name":"Stenoparib","type":"hardware","description":"Novel dual inhibitor of PARP1/2 and tankyrases, in-licensed from Eisai Pharmaceuticals, being developed for platinum-resistant ovarian cancer and relapsed small cell lung cancer."},{"name":"Drug Response Predictor (DRP) Platform","type":"platform","description":"Proprietary bioinformatic platform generating drug-specific companion diagnostics using cancer cell transcriptome analysis to identify patients likely to benefit from specific cancer therapies."},{"name":"Stenoparib-DRP Companion Diagnostic","type":"platform","description":"Companion diagnostic under development to identify ovarian cancer patients most likely to benefit from stenoparib treatment, granted patents in Australia and Europe."},{"name":"Gene Expression and DRP Analysis Services","type":"service","description":"Laboratory services provided to external biotech clients for DRP analysis and gene expression, generating $0.3 million in revenue in 2025."}],"partnerships":[{"partner_name":"Eisai Pharmaceuticals","partnership_type":"licensing","description":"Exclusive worldwide in-license of stenoparib from Japanese pharmaceutical company Eisai Pharmaceuticals.","start_date":null},{"partner_name":"Chosa Oncology (Chosa ApS)","partnership_type":"licensing","description":"Out-licensed DRP companion diagnostic for LiPlaCis and transferred exclusive development rights for LiPlaCis to Chosa ApS, affiliate of Smerud Medical Research International AS.","start_date":null},{"partner_name":"US Veterans Administration","partnership_type":"development","description":"Fully funded randomized trial combining stenoparib with Temozolomide in relapsed small cell lung cancer, opened for enrollment January 2026.","start_date":null}],"affiliations":[],"origin":{"leaf":"e0961216408e6cc577157f871ed8ad5100d5c1aaefe304c41ba2d3afa4983100","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"7878e4845a3afe99fe8b061c4ca681af90b133dd4fcf665de2292a95ace8380e","parent":"36e4ec46cce6206682bd49f74223925b5b5bdfb8488ead19a831b7e9e3d0d47b","source":"0001437749-26-010310","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":88,"hourly_limit":500,"remaining":412,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}